From The British Journal of Cancer ... | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1653 of 1668  at  7/27/2020 9:13:38 AM  by

auh2oman


From The British Journal of Cancer ...

 Below are excerpts from the published abstract mentioning tilsotolimod:
 
 
 

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

British Journal of Cancer (2020)

 
 
 
 
 
 Several studies are investigating whether combining a HIT-IT with ipilimumab can provide additional activity. In a Phase 1/2 trial, addition of the TLR-9 agonist IMO-2125 (tilsotolimod) to ipilimumab revived the immune response in injected and uninjected anti-PD-1-resistant tumours.31 A randomised Phase 3 trial assessing IMO-2125 plus ipilimumab in patients who have progressed on previous anti-PD-1 therapy is ongoing.102
 
 

Table 2 Efficacy of combination therapy with HIT-IT and systemic immunotherapies.
 
 
 https://www.nature.com/articles/s41416-020-0994-4
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 124
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.
Loading...